DDInter517 DDInter1747
Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Dexbrompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Dexbrompheniramine {u} (Compound) resembles {v} (Compound) Bepotastine
Dexbrompheniramine {u} (Compound) resembles {v} (Compound) Captodiame
Dexbrompheniramine {u} (Compound) binds {v} (Gene) KCNH2
Dexbrompheniramine {u} (Compound) downregulates {v} (Gene) IER3
Dexbrompheniramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hyaluronidase
Dexbrompheniramine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Dexbrompheniramine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Dexbrompheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Doxylamine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Dexbrompheniramine (Compound) resembles Bepotastine (Compound)
Dexbrompheniramine (Compound) resembles Captodiame (Compound)
Dexbrompheniramine (Compound) binds KCNH2 (Gene)
Dexbrompheniramine (Compound) downregulates IER3 (Gene)
Dexbrompheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Dexbrompheniramine may lead to a major life threatening interaction when taken with Potassium chloride
Dexbrompheniramine (Compound) resembles Doxylamine (Compound) and Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine